Rubius Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RUBY research report →
Companywww.rubiustx.com
Rubius Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers.
- CEO
- Laurence A. Turka
- IPO
- 2018
- Employees
- 6
- HQ
- Cambridge, MA, US
Price Chart
Valuation
- Market Cap
- $0
- P/E
- -0.02
- P/S
- 0.00
- P/B
- 0.34
- EV/EBITDA
- 0.08
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -238.11%
- ROIC
- -1099.41%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-230,863,000 · -22.26%
- EPS
- $-2.56 · -19.07%
- Op Income
- $-178,446,000
- FCF YoY
- -4.49%
Performance & Tape
- 52W High
- $0.38
- 52W Low
- $0.00
- 50D MA
- $0.02
- 200D MA
- $0.02
- Beta
- 2.21
- Avg Volume
- 99.53K
Get TickerSpark's AI analysis on RUBY
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 24, 23 | Appelhans Dannielle | sell | 10,385 |
| Feb 1, 23 | CAGNONI PABLO J | sell | 8,448 |
| Jan 31, 23 | Appelhans Dannielle | other | 7,500 |
| Jan 31, 23 | Appelhans Dannielle | other | 7,500 |
| Feb 1, 23 | Appelhans Dannielle | sell | 3,878 |
| Jan 31, 23 | CAGNONI PABLO J | other | 25,000 |
| Jan 31, 23 | CAGNONI PABLO J | other | 25,000 |
| Jan 31, 23 | CAGNONI PABLO J | sell | 7,240 |
| Jan 29, 23 | CAGNONI PABLO J | other | 21,250 |
| Jan 29, 23 | CAGNONI PABLO J | other | 21,250 |
Our RUBY Coverage
We haven't published any research on RUBY yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate RUBY Report →